Developer docs
API playgroundTry for free, no card

Search company profiles

Abzyme Therapeutics

Full company profile

uuid000amzr

Namestring
Abzyme Therapeutics
Websiteurl
abzymetx.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Abzyme Therapeutics is a private biopharmaceutical company founded in 2010 and headquartered in Royersford, Pennsylvania. The company is focused on developing modular single domain VHH antibody fragments for use in immunotherapy applications. VHH fragments, derived from camelid heavy-chain-only antibodies, are small-format binding proteins that offer advantages such as improved tissue penetration, thermal stability, and modularity for engineering multi-specific constructs — properties relevant to next-generation immuno-oncology and immune-modulation therapeutics.

The company operates with a very small team of 1-10 employees under the scientific leadership of co-founder and Chief Scientific Officer Hiep Tran. The corporate website (abzymetx.com) was inaccessible at the time of data collection, returning only a verification/waiting page, and no detailed product pipeline, patents, partnerships, clinical milestones, or funding history were disclosed in the available data. There is no indication of an in-licensed or partnered program, no disclosed IND-enabling work, and no evidence of commercial revenue, licensing income, or third-party collaborations.

The business model cannot be definitively characterized from the input. As a private, small-cap preclinical-stage biotech with no disclosed funding rounds, partnerships, or revenue, Abzyme appears to be sustained by founder capital, potential non-dilutive grant funding, or undisclosed angel/seed investment. No pricing models, GTM motion, customer segments, or distribution channels are articulated in the source material. The company serves the biopharmaceutical R&D ecosystem as a potential pipeline developer or licensor of VHH-based therapeutic candidates, but downstream customer relationships, target indications, and development stage remain unconfirmed.

Short descriptiontext

Abzyme Therapeutics is a private, preclinical-stage biopharmaceutical company founded in 2010 in Royersford, Pennsylvania, developing modular single domain VHH antibody fragments for immunotherapy applications under the scientific leadership of co-founder and CSO Hiep Tran.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRoyersford, United States
HQ citystring
Royersford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
single domain antibodies, VHH antibody fragments, antibody therapeutics, immunotherapy development, biopharmaceutical research
Industry2 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Therapeutic Antibodies
No data
Cost components2 values
Personnel, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy applications. The company works on engineering camelid-derived antibody fragments as therapeutic candidates for immune-related disease targets.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Modular VHH Antibody Fragments
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeOthers
Description

Leader in antibody discovery and engineering with a proprietary yeast-based platform serving pharma partners. Comparable as a platform-based antibody discovery company, though it operates as a service/discovery partner rather than a therapeutic developer.

TypeBroad incumbent
Description

The originator of the VHH/nanobody platform (now part of Sanofi following the 2018 acquisition). Highly comparable technology foundation; competes broadly with Abzyme in the same molecular modality space.

TypeBroad incumbent
Description

Antibody-drug conjugate pioneer with multiple clinical-stage programs. Adjacent to Abzyme's VHH immunotherapy focus because nanobodies are increasingly used as targeting arms of next-generation ADCs.

TypeEmerging player
Description

Aberdeen-based preclinical-stage developer of soloMER (humanized VHH) therapeutics. Comparable in modality and scale to Abzyme as an early-stage VHH platform.

5Harbour BioMed
TypeDirect peer
Description

Clinical-stage biotech with a heavy VHH/nanobody franchise (HBM7008 and batoclimab). Closely aligned with Abzyme in platform modality and immunology/immuno-oncology focus.

TypeDirect peer
Description

The leading clinical-stage VHH/nanobody platform company (efgartigimod / VYVGART). Directly comparable to Abzyme as both are built on VHH single-domain antibody technology for immunology indications, though Argenx is a commercial-stage incumbent.

TypeEmerging player
Description

Clinical-stage biotech developing multi-specific antibodies for immuno-oncology. Comparable as a smaller-platform antibody company pursuing modular multi-specific immunotherapies.

TypeBroad incumbent
Description

Major antibody therapeutics company behind multiple approved products (DARZALEX, etc.) with proprietary antibody platforms (DuoBody, HexaBody). Comparable therapeutic-area focus, with a broader, more mature platform portfolio.

TypeDirect peer
Description

UK-based developer of VHH-based T-cell engagers and immune modulators. Directly comparable as a VHH-platform biotech pursuing multi-specific immunotherapies.

TypeBroad incumbent
Description

Clinical-stage biotech developing multi-specific antibody therapeutics for cancer and autoimmune disease. Comparable in therapeutic area (immunotherapy) and antibody-engineering platform approach.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abzyme Therapeutics

Therapeutic Antibodiesabzymetx.com

Abzyme Therapeutics is a private, preclinical-stage biopharmaceutical company founded in 2010 in Royersford, Pennsylvania, developing modular single domain VHH antibody fragments for immunotherapy applications under the scientific leadership of co-founder and CSO Hiep Tran.

What Abzyme Therapeutics does

Abzyme Therapeutics is a private biopharmaceutical company founded in 2010 and headquartered in Royersford, Pennsylvania. The company is focused on developing modular single domain VHH antibody fragments for use in immunotherapy applications. VHH fragments, derived from camelid heavy-chain-only antibodies, are small-format binding proteins that offer advantages such as improved tissue penetration, thermal stability, and modularity for engineering multi-specific constructs — properties relevant to next-generation immuno-oncology and immune-modulation therapeutics.

The company operates with a very small team of 1-10 employees under the scientific leadership of co-founder and Chief Scientific Officer Hiep Tran. The corporate website (abzymetx.com) was inaccessible at the time of data collection, returning only a verification/waiting page, and no detailed product pipeline, patents, partnerships, clinical milestones, or funding history were disclosed in the available data. There is no indication of an in-licensed or partnered program, no disclosed IND-enabling work, and no evidence of commercial revenue, licensing income, or third-party collaborations.

The business model cannot be definitively characterized from the input. As a private, small-cap preclinical-stage biotech with no disclosed funding rounds, partnerships, or revenue, Abzyme appears to be sustained by founder capital, potential non-dilutive grant funding, or undisclosed angel/seed investment. No pricing models, GTM motion, customer segments, or distribution channels are articulated in the source material. The company serves the biopharmaceutical R&D ecosystem as a potential pipeline developer or licensor of VHH-based therapeutic candidates, but downstream customer relationships, target indications, and development stage remain unconfirmed.

Abzyme Therapeutics firmographics

Firmographics
Name
Abzyme Therapeutics
Website
https://abzymetx.com
Company type
Private
Founded year
2010
Headcount range
1–10 employees
Short description
Abzyme Therapeutics is a private, preclinical-stage biopharmaceutical company founded in 2010 in Royersford, Pennsylvania, developing modular single domain VHH antibody fragments for immunotherapy applications under the scientific leadership of co-founder and CSO Hiep Tran.
Ownership category
akta.pro rank

Abzyme Therapeutics industry classification

Industry
Product category
Therapeutic Antibodies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Single domain antibodies
  • VHH antibody fragments
  • Antibody therapeutics
  • Immunotherapy development
  • Biopharmaceutical research

Where Abzyme Therapeutics is headquartered

Location

Headquarters

HQ city
Royersford
HQ country
United States
HQ region
North America

Markets served

Abzyme Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D

Abzyme Therapeutics product offering

Product offering

Core offering

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy applications. The company works on engineering camelid-derived antibody fragments as therapeutic candidates for immune-related disease targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Modular VHH Antibody Fragments

Companies that use Abzyme Therapeutics

Customer profile

Ideal customer profiles1 record

Abzyme Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Abzyme Therapeutics partnerships and signals

Strategic signal

Recent moves1 record

Abzyme Therapeutics competitors and assessment

Company assessment

Others

  • Adimab: Leader in antibody discovery and engineering with a proprietary yeast-based platform serving pharma partners. Comparable as a platform-based antibody discovery company, though it operates as a service/discovery partner rather than a therapeutic developer.

Broad incumbents

  • Ablynx (Sanofi): The originator of the VHH/nanobody platform (now part of Sanofi following the 2018 acquisition). Highly comparable technology foundation; competes broadly with Abzyme in the same molecular modality space.
  • ImmunoGen: Antibody-drug conjugate pioneer with multiple clinical-stage programs. Adjacent to Abzyme's VHH immunotherapy focus because nanobodies are increasingly used as targeting arms of next-generation ADCs.
  • Genmab: Major antibody therapeutics company behind multiple approved products (DARZALEX, etc.) with proprietary antibody platforms (DuoBody, HexaBody). Comparable therapeutic-area focus, with a broader, more mature platform portfolio.
  • MacroGenics: Clinical-stage biotech developing multi-specific antibody therapeutics for cancer and autoimmune disease. Comparable in therapeutic area (immunotherapy) and antibody-engineering platform approach.

Emerging players

  • Elasmogen: Aberdeen-based preclinical-stage developer of soloMER (humanized VHH) therapeutics. Comparable in modality and scale to Abzyme as an early-stage VHH platform.
  • Compass Therapeutics: Clinical-stage biotech developing multi-specific antibodies for immuno-oncology. Comparable as a smaller-platform antibody company pursuing modular multi-specific immunotherapies.

Direct peers

  • Harbour BioMed: Clinical-stage biotech with a heavy VHH/nanobody franchise (HBM7008 and batoclimab). Closely aligned with Abzyme in platform modality and immunology/immuno-oncology focus.
  • Argenx: The leading clinical-stage VHH/nanobody platform company (efgartigimod / VYVGART). Directly comparable to Abzyme as both are built on VHH single-domain antibody technology for immunology indications, though Argenx is a commercial-stage incumbent.
  • Crescendo Biologics: UK-based developer of VHH-based T-cell engagers and immune modulators. Directly comparable as a VHH-platform biotech pursuing multi-specific immunotherapies.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Abzyme Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abzyme Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Abzyme Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abzyme Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abzyme Therapeutics

What does Abzyme Therapeutics do?

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy applications. The company works on engineering camelid-derived antibody fragments as therapeutic candidates for immune-related disease targets.

When was Abzyme Therapeutics founded?

Abzyme Therapeutics was founded in 2010. It employs 1 to 10 people.

Where is Abzyme Therapeutics based?

Abzyme Therapeutics is headquartered in Royersford, United States, in the North America region.

Who are Abzyme Therapeutics's main competitors?

Adimab is listed as an others. Broad incumbents are Ablynx (Sanofi), ImmunoGen, Genmab and MacroGenics. Emerging players are Elasmogen and Compass Therapeutics. Direct peers are Harbour BioMed, Argenx and Crescendo Biologics.

Does Abzyme Therapeutics have an API?

No public API is recorded for Abzyme Therapeutics.

What industry is Abzyme Therapeutics in?

Abzyme Therapeutics's product category is Therapeutic Antibodies. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales